Trial Summary
What is the purpose of this trial?
This trial tests if a pill with fish oil nutrients can help heal stubborn leg wounds in adults aged 55 and older. These wounds are hard to heal because of ongoing inflammation. The fish oil nutrients aim to reduce this inflammation, helping the wounds to heal better. Fish oil has been studied for its anti-inflammatory properties and potential benefits in wound healing.
Do I need to stop taking my current medications for the trial?
You may need to stop certain medications. The trial excludes people taking corticosteroids, COX-2 inhibitors, and NSAIDs more than twice a week, except for aspirin 81 mg/day.
What data supports the idea that Omega-3 Supplements for Leg Ulcers is an effective treatment?
The available research shows that Omega-3 supplements, specifically EPA and DHA from fish oil, can be effective in treating leg ulcers. In a study, patients who took these supplements showed a significant reduction in wound size, with a 57% reduction by Day 28 and a 76% reduction by Day 56, compared to a 35% and 59% reduction in the control group. This suggests that Omega-3 supplements help reduce inflammation and promote healing in leg ulcers. Additionally, fish skin grafts containing Omega-3 have been shown to speed up healing and result in more fully healed wounds compared to standard treatments.12345
What safety data exists for omega-3 supplements in treating leg ulcers?
The studies reviewed indicate that omega-3 fatty acids, specifically EPA and DHA from fish oil, have been tested for their effects on chronic venous leg ulcers and other chronic wounds. These studies suggest that omega-3 supplements can reduce inflammation and promote wound healing without reporting significant adverse effects. However, specific safety data or adverse events related to omega-3 supplementation in these trials are not detailed in the provided abstracts.12345
Is the treatment EPA+DHA a promising treatment for leg ulcers?
Research Team
Jodi C McDaniel, PhD, RN
Principal Investigator
Ohio State University, College of Nursing
Eligibility Criteria
This trial is for men and women aged 55 or older with chronic venous leg ulcers between the ankle and knee, present for 4 weeks to 12 months. Participants must have a wound area of 2-60 cm2, understand English or Spanish, have certain blood flow levels in their legs (ABPI of 0.7-1.2), be on prescribed compression therapy, and able to consent. Excluded are those taking certain anti-inflammatory drugs more than twice a week (except low-dose aspirin), with fish allergies, autoimmune diseases, poorly controlled diabetes or recent chemotherapy.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- EPA+DHA (Omega-3 Fatty Acid)
- placebo (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University
Lead Sponsor
Dr. John J. Warner
Ohio State University
Chief Executive Officer since 2023
MD, MBA
Dr. Peter Mohler
Ohio State University
Chief Medical Officer since 2023
PhD in Molecular Biology
National Institute on Aging (NIA)
Collaborator
Dr. Richard J. Hodes
National Institute on Aging (NIA)
Chief Executive Officer since 1993
MD from Harvard Medical School
Dr. Marie Bernard
National Institute on Aging (NIA)
Chief Medical Officer
MD from Harvard Medical School